Hoping Drugs Take Root, Alder Raises $38 Million Round
This article was originally published in The Pink Sheet Daily
The Bothell, Wash.-based antibody developer will study a Phase II interleukin-6 inhibitor in cancer indications, and will bring a new migraine drug into the clinic. The IL-6 drug is already partnered with BMS in a lucrative deal for autoimmune indications.
You may also be interested in...
Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential
After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.
Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care
Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.
Alder Obtains First Milestone Under BMS Deal, Advances Own Program In Cancer Supportive Care
Privately held biotech earns $15 million as Bristol Myers Squibb readies interleukin-6 inhibitor for Phase IIb dose-ranging trial in rheumatoid arthritis.